Immunic (IMUX) Total Current Liabilities (2013 - 2026)

Immunic has reported Total Current Liabilities for 14 years, with the latest figure at $38.4 million in Q1 2026.

• Quarterly Total Current Liabilities rose 49.9% year-over-year to $38.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.4 million (up 49.9% YoY) and the FY2025 annual result came in at $30.6 million, up 38.07% from the prior year.
• Total Current Liabilities climbed to $38.4 million in Q1 2026 per IMUX's latest filing, from $30.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $38.4 million in Q1 2026 and troughed at $10.4 million in Q2 2022.
• A 5-year average of $21.4 million and a median of $22.2 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities decreased 29.95% in 2022, then surged 89.1% in 2023.
• Over 5 years, Total Current Liabilities stood at $13.1 million in 2022, then soared by 89.1% to $24.7 million in 2023, then fell by 10.33% to $22.2 million in 2024, then jumped by 38.07% to $30.6 million in 2025, then climbed by 25.3% to $38.4 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $38.4 million, $30.6 million, and $30.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.